Company / EPS (Diluted)
10x Genomics, Inc. EPS (Diluted) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$2.18
FY2025
5-year range
-$5.37 / -$0.53
FY2021-FY2025
Trend
-49.3%
vs FY2024
Sector context
#135 of 159
Health Care
What the data says
10x Genomics, Inc.'s eps (diluted) of $-2.18 is lower than 85% of companies in the Health Care sector (FY2025). EPS (Diluted) has fluctuated over the past 7 years, ranging from $-8.40 in FY2020 to $-0.53 in FY2023.
Based on SEC 10-K filings.
-2.18 in FY2025.
Declined from $-0.53 to $-2.18 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 15% in Health CareTop 85% of 159This company -$2.18 Sector average $1.64
▼
-233.1% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 49.3% year-over-year.
- Ranks #135 out of 159 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2023.
- Lowest eps (diluted) in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -29.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.18 | -49.3% |
| FY2024 | -$1.46 | -175.5% |
| FY2023 | -$0.53 | +90.1% |
| FY2022 | -$5.37 | -571.3% |
| FY2021 | -$0.80 | +90.5% |
| FY2020 | -$8.40 | -418.5% |
| FY2019 | -$1.62 | - |
| FY2018 | - | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026